Cagrilintide + Semaglutide Blend (10mg Total)
5mg + 5mg (10mg)
$190.00
Cagrilintide + Semaglutide Blend (10mg Total)
High-Concentration Dual Amylin & GLP-1 Receptor Agonist Complex
The 4Balance Codex: The High-Potency Architecture of Dual-Pathway Metabolic Control.
Product Overview
This product is a high-concentration, fixed-dose co-formulation containing equal parts Cagrilintide (5mg) and Semaglutide (5mg), yielding a total vial mass of 10mg. Designed for advanced metabolic research requiring robust agonist concentrations, this blend facilitates the investigation of potent, additive synergy between the incretin and amylin signaling pathways. It is the primary research tool for exploring maximal efficacy in body weight regulation and glucose homeostasis models that exceed the capabilities of standard-dose monotherapies.
Format: Lyophilized Powder (Co-formulated concentrate) Total Mass: 10mg Composition: 5mg Cagrilintide / 5mg Semaglutide
Mechanism of Action: Convergent Neuroendocrine Signaling
The scientific rationale for this concentrated blend lies in simultaneously targeting distinct, complementary neuronal populations within the central nervous system to maximize satiety and metabolic efficacy.
The GLP-1 Vector (Semaglutide - 5mg): An acylated human GLP-1 analogue that binds to GLP-1 receptors in the hypothalamus (arcuate nucleus) and hindbrain. Its activation stimulates glucose-dependent insulin secretion, suppresses glucagon release, and promotes strong sensations of satiation (fullness).
The Amylin Vector (Cagrilintide - 5mg): A long-acting, non-selective amylin/calcitonin receptor agonist. It targets specific receptors in the hindbrain (area postrema and nucleus of the solitary tract), areas less accessible to GLP-1 alone. This activation enhances satiety signals and significantly slows gastric emptying.
Concentrated Synergistic Amplification: By engaging divergent neural circuits that converge on energy balance regulation, this high-dose combination produces a more profound and sustained physiological response than either compound administered individually. The distinct mechanisms allow for multi-modal, high-potency control of appetite and glycemic parameters.
Research Applications
In the 4Balance Research Array, this concentrated 10mg blend is utilized to study advanced and resistant metabolic states.
Maximal Efficacy Obesity Models: Investigating the upper limits of weight loss synergy (the "CagriSema" effect) in models of severe obesity that may be resistant to lower-dose interventions.
Deep Glycemic Control: Used to study potent HbA1c reduction and beta-cell preservation in advanced Type 2 Diabetes models where significant insulin sensitization and glucagon suppression are required.
Dose-Response Synergy Mapping: Utilizing high-concentration blends to establish the ceiling effects of dual agonism versus single-pathway saturation.
Technical Specifications
Total Vial Content: 10mg Lyophilized Peptide Complex
Component Ratio: 1:1 (by mass)
Active Ingredient 1: Cagrilintide (5mg) - Long-acting Amylin Analogue
Active Ingredient 2: Semaglutide (5mg) - Long-acting GLP-1 Receptor Agonist
Solubility: Water Soluble (Requires Bacteriostatic Water for reconstitution. Due to concentration, ensure thorough but gentle mixing).
Storage: Store lyophilized at -20°C. Once reconstituted, handle with care due to the complex nature of the co-formulation.
References
Kruse, T., et al. (2021). The long-acting amylin analogue cagrilintide, developed for treatment of obesity and type 2 diabetes, results in significant weight loss and improvement in glycemic control in obese and diabetic rats. Journal of Medicinal Chemistry.
Lau, J., et al. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry.
Boyle, C. N., et al. (2018). Amylin's primary action in the brain is neuroendocrine, not anorexigenic. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology.
Frias, J. P., et al. (2023). Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) in people with type 2 diabetes: a randomised, double-blind, controlled phase 2 trial. The Lancet Diabetes & Endocrinology.
Enebo, L. B., et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide in subjects with overweight or obesity: a randomised, controlled, phase 1b trial. The Lancet.
DISCLAIMER: FOR RESEARCH USE ONLY. This product is a laboratory reagent intended strictly for in-vitro research and development. It is not for human consumption, veterinary use, or therapeutic application. Bodily introduction of any kind is strictly prohibited by law.
